This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration has approved a prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster). MONDAY, July 21, 2025 -- The U.S. The existing vaccine consists of two.
The early results are highly promising: all the babies are developing normally, and the disease-causing mutations are undetectable or present at levels too low to cause harm. The process, known as pronuclear transfer, was designed to prevent the inheritance of devastating mitochondrial diseases passed down through the mother’s DNA.
This work presents the identification and early-stage optimization of small molecule fragment-like stabilizers for a specific binding site of the 14-3-3/Tau PPI.
Herein, we present an implicit equation that can estimate these constants from incubation time-dependent IC50 values and a numerical modelling method, EPIC-CoRe, that can fit these kinetic parameters from pre-incubation time-dependent IC50 data.
These compounds bring together two proteins in the cell that might not normally find each other a target protein (often the one altered in disease), and a presenter protein that has some effect on the target. For their presenter protein, they chose FKBP12, a well-studied protein that is abundant in human cells.
Climate scientists present a realistic supercomputer simulation that resolves the complex interactions between fire, vegetation, smoke and the atmosphere. The authors find that increasing greenhouse gas emissions will likely increase the global lightning frequency by about 1.6%
This work presents a comprehensive analysis of oxygen atoms in approved drugs, aiming to streamline drug design and discovery efforts. In approved drugs, majority of oxygen atoms are present within 4 from the COM of the molecule.
The largest sample of galaxy groups ever detected has been presented by a team of international astronomers using data from the James Webb Space telescope (JWST) in an area of the sky called COSMOS Web.
The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.
We are proud to present for the first time the primary analysis data from the MZL cohort of TRANSCEND FL. This underscores our ongoing commitment to unlocking the full potential of cell therapy to aid patients living with relapsed or refractory disease.
Herein, we present mutational and structural investigations on understudied ubiquitous MtCK that showed closure of the loop comprising His61 is specific to and relies on creatine binding and mechanism of phosphoryl transfer depends on electrostatics of active site.
Here, we demonstrate the utility of a high-throughput in vitro screening platform along with a comprehensive panel to aid in the characterization of 15 Brutons tyrosine kinase (BTK) inhibitors that are either approved by the FDA or presently under clinical evaluation.
At present, there are few studies on the drug resistance of mIDH1 inhibitors. Isocitrate dehydrogenase (IDH) is a key metabolic enzyme that catalyzes the conversion of isocitrate to -ketoglutaric acid (-KG).
Held at a pivotal juncture for the company, the R&D Day offered an opportunity for BeOne’s executive and scientific leaders to present new clinical data, pipeline milestones, and strategic insights that reaffirm its mission: to build the world’s first next-generation oncology company.
One of the most persistent challenges remains the control group, which can slow recruitment, prolong timelines and present ethical concerns. “In Solving old problems in new ways Herne is well acquainted with the operational inefficiencies that persist across clinical development.
The preclinical data we presented in an oral presentation at AACR, demonstrate the broader anti-tumour activity of dual-targeting ABBV-969 compared to ADCs targeting either STEAP1 or PSMA.” We believe that the pathways targeted with this combination will provide synergistic benefits for patients.”
ABSTRACT This study presents the design, synthesis, and biological evaluation of a series of novel pyrrole-tethered bisbenzoxazole (PTB) derivatives as potential apoptosis-inducing agents targeting the MCF-7 human breast cancer cell line. These findings position PTB derivatives as promising candidates for targeted breast cancer therapy.
However, standard preclinical safety assessment studies may not accurately predict adverse events in humans, particularly with emerging modalities like precision medicine targeting human antigens or genes not present in preclinical species. For use as endpoints, biomarkers must be correlated to a valid clinical outcome.
DARPin therapeutics were a prominent theme at AACR 2025 , with Molecular Partners presenting a trio of preclinical programmes spanning radiopharmaceuticals and immune cell engagers. “Our first presentation at AACR was on IND-enabling preclinical data for MP0712,” Croset explains. ” From there, things moved fast.
Nevertheless, developing such complex models presents enormous technical challenges. Researchers could focus their resources on candidates with the highest probability of success, design more targeted trials and potentially reduce the number of trial participants needed to demonstrate efficacy and safety.
Engineering against resistance: the case of AP402 HER2-positive breast cancer already presents a therapeutic challenge, marked by aggressive tumour growth driven by overexpression of the HER2 receptor. His work centres on the OmniMab and T-cube platforms, which are designed to improve how antibodies are identified, targeted and controlled.
The STELLAR trial, presented at the American College of Cardiology’s 72nd Annual Scientific Session (ACC.23), The STELLAR trial, presented at the American College of Cardiology’s 72nd Annual Scientific Session (ACC.23), ZENITH, the second pivotal Phase 3 trial, presented at ACC.25
Arvinas and Pfizer, which presented a fuller picture of their vepdegestrant study at the American Society of Clinical Oncology’s annual meeting last month, filed an application for approval to the Food and Drug Administration on June 6. SOURCE: Companies What’s next for targeted protein degradation?
In this recorded presentation, a member of Quanticate's statistical programming team explores the creation of two ADaM datasets; ADPC and ADPP for Pharmacokinetic (PK) Analysis.
Where science meets strategy The discovery of tens of thousands of novel proteins presents a clear challenge of determining which to prioritise. Instead, ProFound prioritises only the most promising candidates, applying wet lab resources where the computational insights say it matters most.
Biology, however, presents a unique challenge: it is deeply contextual, dynamic and multilayered. AI’s power in other fields – like protein folding, image recognition and molecular docking – has shown what’s possible when the right models are paired with the correct data.
The data were featured as part of four oral presentations selected by the Associated Professional Sleep Societies (APSS) for their scientific innovation and clinical relevance, with Jazz accounting for all the industry-sponsored late-breaking oral presentations at the meeting.
While treating rare diseases presents significant challenges due to small patient populations and limited financial incentives, the Orphan Products Grants Program provides crucial financial support to help bridge the gap between early research and successful treatment development.
Foundation, explained during the EULAR 2025 presentation: “IgG4-related disease is a progressive, immune-mediated condition with a significant unmet patient need. Importantly, most participants presented with active disease in at least one organ , with the exception of the lymph nodes.
Thus, the presented review will help medicinal chemists in designing anticancer molecules with piperazines. This review highlights the recently reported methods of synthesis of fused/substituted piperazines, structureactivity relationship, and interactions with targets/receptors as anticancer agents.
The data were presented during the 2025 European Hematology Association (EHA) Congress (Abstract #S239). JNJ-4496, previously called C-CAR039, is a novel anti-CD19/anti-CD20 bispecific autologous CAR T-cell therapy designed to enable dual binding to both CD19 and CD20 — two surface proteins frequently present on malignant B-cells.
The data were revealed during an oral presentation (S137) at the 2025 European Hematology Association (EHA) Congress in Vienna, reflecting ongoing progress in developing new treatment options for patients battling this aggressive hematologic malignancy.
Notably, research presented by BMS at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting confirmed that the overwhelming majority of serious side effects like CRS and NTs occur within the first two weeks of treatment , making extended monitoring beyond that period largely unnecessary.
Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized Regenxbio’s Duchenne data and a brain drug study failed.
In this study, we present a series of 2-phenyl- N -(pyridin-2-yl)acetamides in an attempt to investigate their possible antimycobacterial activity, cytotoxicity on the HepG2 liver cancer cell line, andas complementary testingtheir antibacterial and antifungal properties against a panel of clinically important pathogens.
large volume auto-injectors), could unlock hard-to-copy drug presentations that provide meaningful commercial differentiation. Microgravity crystallization, in combination with modern innovations in antibody engineering (e.g., half-life extension) and formulation / delivery (e.g., Access to and reliance on the ISS is a bottleneck.
These mutations are present in approximately 10 percent of patients across all genetic disorders, meaning that people with different diagnoses may share a common genetic mutation.
today presented new and significant data demonstrating the superiority of Dupixent® (dupilumab) over Xolair® (omalizumab) in a first-of-its-kind, head-to-head, Phase 4 study in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and co-existing asthma.
Additional trial results are expected to be presented at upcoming medical conferences and published in peer-reviewed journals throughout 2025 and 2026. Novo Nordisk has stated its intention to submit Mim8 for regulatory approval in 2025, contingent on data from the broader FRONTIER program.
” Hosseini-Gerami specifically mentioned the work of Anne Carpenter’s group and her former colleague Srijit, noting a recent presentation that combined “information from cell painting, from gene expression and from chemical structure, and encoding that within a representation of a molecule to use for machine learning.”
The interim data, presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, California, offer a strong signal of therapeutic potential.
Elise connected me with Celia, who has been a great collaborator and thinker and who knows a lot about the community, and we invited Jenny to help us develop HEARD, to moderate discussions, and to present her own research. Phan : Im one of the newer perspectives entering into this conversation.
In this article, we present the synthesis of novel 3-phenyl-1-((1-aryl-1 H -1,2,3-triazol-5-yl)methyl)spiro[indoline-3,2-oxiran]-2-one derivatives by the regioselective reaction of sulfur ylides with 1,2,3-triazole-tethered isatins and their anticancer effects on hepatocellular carcinoma (HCC) cells HepG2 and HCCLM3.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content